These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 16226797)

  • 1. Abraxane in the treatment of ovarian cancer: the absence of hypersensitivity reactions.
    Micha JP; Goldstein BH; Birk CL; Rettenmaier MA; Brown JV
    Gynecol Oncol; 2006 Feb; 100(2):437-8. PubMed ID: 16226797
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Advanced ovarian cancer: a clinical update on first-line treatment, recurrent disease, and new agents.
    Ozols RF
    J Natl Compr Canc Netw; 2004 Sep; 2 Suppl 2():S60-73. PubMed ID: 19780247
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Single-dose dexamethasone paclitaxel premedication.
    Micha JP; Rettenmaier MA; Dillman R; Fraser P; Birk C; Brown JV
    Gynecol Oncol; 1998 May; 69(2):122-4. PubMed ID: 9600818
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Incidence and risk factors for paclitaxel hypersensitivity during ovarian cancer chemotherapy.
    Sendo T; Sakai N; Itoh Y; Ikesue H; Kobayashi H; Hirakawa T; Nakano H; Oishi R
    Cancer Chemother Pharmacol; 2005 Jul; 56(1):91-6. PubMed ID: 15791461
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Paclitaxel and carboplatin chemotherapy administered during pregnancy for advanced epithelial ovarian cancer.
    Méndez LE; Mueller A; Salom E; González-Quintero VH
    Obstet Gynecol; 2003 Nov; 102(5 Pt 2):1200-2. PubMed ID: 14607056
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hypersensitivity reactions in paclitaxel treatment of ovarian cancer patients.
    Lehoczky O; Bagaméri A; Udvary J; Pulay T
    J Obstet Gynaecol; 2002 May; 22(3):312-3. PubMed ID: 12521509
    [No Abstract]   [Full Text] [Related]  

  • 7. Abraxane for the treatment of gynecologic cancer patients with severe hypersensitivity reactions to paclitaxel.
    Fader AN; Rose PG
    Int J Gynecol Cancer; 2009 Oct; 19(7):1281-3. PubMed ID: 19820391
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II evaluation of nanoparticle albumin-bound paclitaxel in platinum-sensitive patients with recurrent ovarian, peritoneal, or fallopian tube cancer.
    Teneriello MG; Tseng PC; Crozier M; Encarnacion C; Hancock K; Messing MJ; Boehm KA; Williams A; Asmar L
    J Clin Oncol; 2009 Mar; 27(9):1426-31. PubMed ID: 19224848
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improved tolerance of primary chemotherapy with reduced-dose carboplatin and paclitaxel in elderly ovarian cancer patients.
    Fader AN; von Gruenigen V; Gibbons H; Abushahin F; Starks D; Markman M; Belinson J; Rose P
    Gynecol Oncol; 2008 Apr; 109(1):33-8. PubMed ID: 18261784
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Taxol (paclitaxel) as second-line therapy in breast and ovarian cancer].
    Borovik R; Steiner M; Atad J; Sneiderman B; Rosenberg T; Palti S
    Harefuah; 1998 Apr; 134(8):605-8, 671. PubMed ID: 10911422
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Four cycles of paclitaxel and carboplatin as adjuvant treatment in early-stage ovarian cancer: a six-year experience of the Hellenic Cooperative Oncology Group.
    Bamias A; Papadimitriou C; Efstathiou E; Rodolakis A; Vlahos G; Voulgaris Z; Bozas G; Fountzilas G; Aravantinos G; Razis E; Gika D; Dimopoulos MA
    BMC Cancer; 2006 Sep; 6():228. PubMed ID: 16999858
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety of cisplatin after severe hypersensitivity reactions to carboplatin in patients with recurrent ovarian carcinoma.
    Ottaiano A; Tambaro R; Greggi S; Prato R; Di Maio M; Esposito G; Scala F; Barletta E; Losito S; De Vivo R; Iaffaioli VR; Pignata S
    Anticancer Res; 2003; 23(4):3465-8. PubMed ID: 12926091
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Comparison of therapeutic efficacy between TP regimen and CBP regimen on epithelial ovarian cancer after optimal cytoreductive operation].
    Gao KF; Liu FY; Chen FJ; Feng YL
    Ai Zheng; 2007 Apr; 26(4):431-4. PubMed ID: 17430668
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase II trial of paclitaxel poliglumex in recurrent or persistent ovarian or primary peritoneal cancer (EOC): a Gynecologic Oncology Group Study.
    Sabbatini P; Sill MW; O'Malley D; Adler L; Secord AA;
    Gynecol Oncol; 2008 Dec; 111(3):455-60. PubMed ID: 18829087
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The combination of monthly carboplatin and weekly paclitaxel is highly active for the treatment of recurrent ovarian cancer.
    Hoekstra AV; Hurteau JA; Kirschner CV; Rodriguez GC
    Gynecol Oncol; 2009 Dec; 115(3):377-81. PubMed ID: 19800107
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Albumin-bound paclitaxel (Abraxane) for advanced breast cancer.
    Med Lett Drugs Ther; 2005 May; 47(1208):39-40. PubMed ID: 15880087
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Reinduction of paclitaxel therapy after a successfully treated hypersensitivity reaction].
    Lehoczky O; Bagaméri A; Pulay T
    Orv Hetil; 2002 Sep; 143(38):2189-91. PubMed ID: 12395475
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prospective evaluations of continuous weekly paclitaxel regimen in recurrent platinum-resistant epithelial ovarian cancer.
    Le T; Hopkins L; Baines KA; Rambout L; Al Hayki M; Kee Fung MF
    Gynecol Oncol; 2006 Jul; 102(1):49-53. PubMed ID: 16375951
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pegylated liposomal doxorubicin in heavily pretreated epithelial ovarian cancer patients.
    Gorumlu G; Kucukzeybek Y; Kemal-Gul M; Karaca B; Cosan-Terek M; Karabulut B; Sanli UA; Akman L; Ozsaran A; Dikmen Y; Uslu R
    J BUON; 2008; 13(3):349-52. PubMed ID: 18979548
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Pharmacotherapy in ovarian carcinoma].
    Pfisterer J; Du Bois A
    MMW Fortschr Med; 2005 Oct; 147(43):34-6. PubMed ID: 16302419
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.